alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 6,126–6,150 of 10,985 studies · free to read (page 246 of 440) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated Caspase-6 activation

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Cell death and differentiation 2015-03-06

Neuronal active Caspase-6 (Casp6) is associated with Alzheimer disease (AD), cognitive impairment, and axonal degeneration. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Impact of HMGB1, RAGE, and TLR4 in Alzheimer's Disease (AD): From Risk Factors to Therapeutic Targeting

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Cells 2020-02-07

Alzheimer's disease (AD) is a devastating neurodegenerative disorder and a leading cause of dementia, with accumulation of amyloid-beta (Aβ) and neurofibrillary tangles (NFTs) as defining pathological features. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Hypertension induces brain β-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Hypertension (Dallas, Tex. : 1979) 2012-05-21

Although epidemiological data associate hypertension with a strong predisposition to develop Alzheimer disease, no mechanistic explanation exists so far. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Role of neuroinflammation in neurodegeneration: new insights

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer's research & therapy 2017-03-04

Previously, the contribution of peripheral infection to cognitive decline was largely overlooked however, the past 15 years have established a key role for infectious pathogens in the progression of age-related neurodegeneration. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neuronal death induced by nanomolar amyloid β is mediated by primary phagocytosis of neurons by microglia

✓ Peer-reviewed alzhub usefulness score 48 out of 100. The Journal of biological chemistry 2011-09-08

Alzheimer disease is characterized by neuronal loss and brain plaques of extracellular amyloid β (Aβ), but the means by which Aβ may induce neuronal loss is not entirely clear. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Drug repositioning and repurposing for Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Nature reviews. Neurology 2020-09-16

Drug repositioning and repurposing can enhance traditional drug development efforts and could accelerate the identification of new treatments for individuals with Alzheimer disease (AD) dementia and mild cognitive impairment. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Iron loading is a prominent feature of activated microglia in Alzheimer's disease patients

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Acta neuropathologica communications 2021-02-17

Brain iron accumulation has been found to accelerate disease progression in amyloid-β(Aβ) positive Alzheimer patients, though the mechanism is still unknown. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

In vivo detection of microglial activation in frontotemporal dementia

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Annals of neurology 2004-12-01

Using positron emission tomography and [(11)C](R)-PK11195, a marker of "peripheral benzodiazepine sites" that is upregulated on activated microglia during progressive tissue pathology, we show increased binding of [(11)C](R)-PK11195 in frontotemporal lobar degeneration in the typically affected frontotemporal brain regions. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Non-economic social deprivation and cognitive functioning later in life: Results from the DELCODE study

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of Alzheimer s Disease 2026-05-11

Our findings suggest that non-economic social deprivation, especially in terms of access to a grocery store, pharmacy, postal office, and bus stop, might be relevant for maintaining cognitive functioning in old age. 4 key findings →

Design: longitudinal study Participants: 91 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Key lessons to improve care—factors contributing to delayed discharges and cost implications: medical conditions and rehabilitation delays at a tertiary rehabilitation center in Saudi Arabia

✓ Peer-reviewed alzhub usefulness score 48 out of 100. International Journal for Quality in Health Care 2024-04-01

TBI had the highest percentage (37%) compared to other conditions, which may be attributed to the prevalent challenge of cognitive impairment in TBI in addition to physical disability. 5 key findings →

Design: cohort study Participants: 2,285 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Adapting prescribing criteria for amyloid‐targeted antibodies for adults with Down syndrome

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer s & Dementia 2024-03-13

Prior authorization criteria for Federal Drug Administration (FDA) approved immunotherapeutics, among the class of anti-amyloid monoclonal antibodies (mAbs), established by state drug formulary committees, are tailored for adults with late-onset Alzheimer's disease. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Identification of prevalent dementia in Medicare Advantage encounters, compared with rigorous cohort assessments

✓ Peer-reviewed alzhub usefulness score 48 out of 100. The Journals of Gerontology Series A 2026-08-24

Of the 508 eligible MA enrollees, mean age was 82.8 (SD = 7.2) years, 81% were female, and 49% were non-Latino White; 62 participants (12%) were classified as having dementia by the cohort assessment. 5 key findings →

Design: cohort study Participants: 62 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A Comprehensive, Community‐Engaged Recruitment Strategy to Increase Minority Representation in New IDEAS – an Amyloid Imaging Study

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer s & Dementia 2023-12-01

To ensure diversity, we developed a comprehensive recruitment strategy using a diverse, culturally‐trained staff that includes : • Identifying Dementia Specialists experienced recruiting minorities • Embedding high‐impact community engagement in select regions • Increasing capacity of specialists and PET facilities to engage minorities • Increasing pipeline of referrals to Dementia Specialists • Creating a culturally‐informed awareness campaign Result New IDEAS has enrolled 4,524 participants including 954 (21.1%) Black/African American, and 842 (18.6%) Hispanic/Latinx. 3 key findings →

Design: cohort study Participants: 4,524 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Prevalence of dementia and major dementia subtypes in Spanish populations: A reanalysis of dementia prevalence surveys, 1990-2008

✓ Peer-reviewed alzhub usefulness score 48 out of 100. BMC Neurology 2009-10-19

The reanalyzed study population (aged 70 year and above) was composed of Central and North-Eastern Spanish sub-populations obtained from 9 surveys and totaled 12,232 persons and 1,194 cases of dementia (707 of Alzheimer's disease, 238 of vascular dementia). 5 key findings →

Participants: 12,232 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Projected extreme temperature event-attributable dementia deaths in China: a climate–ageing–adaptation framework

✓ Peer-reviewed alzhub usefulness score 48 out of 100. EBioMedicine 2025-12-09

Without adaptation, ADD heatwave-attributable deaths are projected to rise sharply, especially under rapid socioeconomic development with high greenhouse gas emissions scenario (SSP5-RCP8.5) in the 2080s, which reach 59,088-an 11-fold (+1003%) increase comparing to 2010s levels. 5 key findings →

Participants: 399,036 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed